Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25466181)

  • 1. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
    Kozakai Y; Kamada R; Kiyota Y; Yoshimura F; Tanino K; Sakaguchi K
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5593-5596. PubMed ID: 25466181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small molecule inhibitor of p53-inducible protein phosphatase PPM1D.
    Yagi H; Chuman Y; Kozakai Y; Imagawa T; Takahashi Y; Yoshimura F; Tanino K; Sakaguchi K
    Bioorg Med Chem Lett; 2012 Jan; 22(1):729-32. PubMed ID: 22115592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel inhibitors targeting PPM1D phosphatase potently suppress cancer cell proliferation.
    Ogasawara S; Kiyota Y; Chuman Y; Kowata A; Yoshimura F; Tanino K; Kamada R; Sakaguchi K
    Bioorg Med Chem; 2015 Oct; 23(19):6246-9. PubMed ID: 26358280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
    Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
    Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines.
    Cheeseman MD; Faisal A; Rayter S; Barbeau OR; Kalusa A; Westlake M; Burke R; Swan M; van Montfort R; Linardopoulos S; Jones K
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3469-74. PubMed ID: 24953599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax.
    Kong W; Jiang X; Mercer WE
    Cancer Biol Ther; 2009 Mar; 8(6):555-63. PubMed ID: 19242108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
    Pärssinen J; Alarmo EL; Karhu R; Kallioniemi A
    Cancer Genet Cytogenet; 2008 Apr; 182(1):33-9. PubMed ID: 18328948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of protein phosphatase magnesium-dependent 1 (PPM1D) through lentivirus-mediated RNA silencing inhibits colorectal carcinoma cell proliferation.
    Yin H; Yan Z; Liang Y; Liu B; Su Q
    Technol Cancer Res Treat; 2013 Dec; 12(6):537-43. PubMed ID: 23745790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells.
    Kamada R; Kudoh F; Yoshimura F; Tanino K; Sakaguchi K
    J Biochem; 2017 Oct; 162(4):303-308. PubMed ID: 28486685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
    Lu X; Nannenga B; Donehower LA
    Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
    Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
    J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D.
    Chuman Y; Yagi H; Fukuda T; Nomura T; Matsukizono M; Shimohigashi Y; Sakaguchi K
    Protein Pept Lett; 2008; 15(9):938-48. PubMed ID: 18991770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
    Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
    Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38.
    Zhang M; Xu E; Zhang J; Chen X
    Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
    Proia DA; Nannenga BW; Donehower LA; Weigel NL
    J Biol Chem; 2006 Mar; 281(11):7089-101. PubMed ID: 16352595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
    Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
    Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncated PPM1D Prevents Apoptosis in the Murine Thymus and Promotes Ionizing Radiation-Induced Lymphoma.
    Martinikova AS; Burocziova M; Stoyanov M; Macurek L
    Cells; 2020 Sep; 9(9):. PubMed ID: 32927737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
    Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
    Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.